Gelteq Ltd. operates as a biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 7 full-time employees. The company went IPO on 2024-10-29. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
GELS stock price ended at $0.8 on 水曜日, after rising 0.00%
On the latest trading day Feb 11, 2026, the stock price of GELS rose by 0.00%, climbing from $0.79 to $0.80. During the session, the stock saw a volatility of 12.33%, with prices oscillating between a daily low of $0.73 and a high of $0.82. Notably, trading volume dropped by 99.5K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 111.2K shares were traded, equating to a market value of approximately $8.5M.